Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Muralidhar V, et al. Among authors: chen yw. Urol Oncol. 2015 Jul;33(7):330.e19-25. doi: 10.1016/j.urolonc.2015.03.010. Epub 2015 May 16. Urol Oncol. 2015. PMID: 25990612
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, Rathmell WK, Rini BI, Zhang T. Tucker MD, et al. Among authors: chen yw. Biomark Res. 2021 Nov 3;9(1):80. doi: 10.1186/s40364-021-00334-4. Biomark Res. 2021. PMID: 34732251 Free PMC article.
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
Chen YW, Tucker MD, Brown LC, Yasin HA, Ancell KK, Armstrong AJ, Beckermann KE, Davis NB, Harrison MR, Kaiser EG, McAlister RK, Schaffer KR, Wallace DE, George DJ, Rathmell WK, Rini BI, Zhang T. Chen YW, et al. Cancers (Basel). 2022 Aug 7;14(15):3830. doi: 10.3390/cancers14153830. Cancers (Basel). 2022. PMID: 35954493 Free PMC article.
Emerging Targets in Clear Cell Renal Cell Carcinoma.
Chen YW, Rini BI, Beckermann KE. Chen YW, et al. Cancers (Basel). 2022 Oct 4;14(19):4843. doi: 10.3390/cancers14194843. Cancers (Basel). 2022. PMID: 36230766 Free PMC article. Review.
2,486 results